AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ARS Pharmaceuticals, Inc. Director's Dealing 2025

May 22, 2025

32159_dirs_2025-05-22_edb3101a-a4dd-43f0-9445-bd793fd8f04c.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ARS Pharmaceuticals, Inc. (SPRY)
CIK: 0001671858
Period of Report: 2025-05-20

Reporting Person: SAUNDERS BRENT L (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-05-20	Common Stock	M	120000	$1.01	Acquired	120000	Direct
2025-05-20	Common Stock	S	120000	$14.2502	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-05-20	Stock Option (Right to Buy)	$1.01	M	120000	Disposed	2031-06-15	Common Stock (120000)	Direct

Footnotes

F1: The weighted average sale price for the transaction reported was $14.2502 and the range of prices were between $14.25 and $14.26. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

F2: Immediately exercisable.